The estimated Net Worth of Ghiath M.Gms Ventures & Inv... is at least $196 millió dollars as of 29 November 2021. Ghiath Inv owns over 16,000,000 units of Outlook Therapeutics Inc stock worth over $195,674,827 and over the last 5 years Ghiath sold OTLK stock worth over $0.
Sign up
Ghiath Inv OTLK stock SEC Form 4 insiders trading
Ghiath has made over 2 trades of the Outlook Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Ghiath bought 16,000,000 units of OTLK stock worth $20,000,000 on 29 November 2021.
The largest trade Ghiath's ever made was buying 16,000,000 units of Outlook Therapeutics Inc stock on 29 November 2021 worth over $20,000,000. On average, Ghiath trades about 3,480,000 units every 43 days since 2020. As of 29 November 2021 Ghiath still owns at least 27,834,257 units of Outlook Therapeutics Inc stock.
You can see the complete history of Ghiath Inv stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Outlook Therapeutics Inc
Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv... és Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.
What does Outlook Therapeutics Inc do?
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
What does Outlook Therapeutics Inc's logo look like?
Complete history of Ghiath Inv stock trades at Outlook Therapeutics Inc
Outlook Therapeutics Inc executives and stock owners
Outlook Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Lawrence Kenyon,
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director -
Lawrence A. Kenyon CPA,
Exec. VP, CFO, Treasurer, Company Sec. & Director -
C. Russell Trenary III,
Pres, CEO & Director -
Randy Thurman,
Executive Chairman of the Board -
Terry Dagnon,
Chief Operations Officer -
Jeffrey Evanson,
Chief Commercial Officer -
Ralph H. Thurman,
Independent Exec. Chairman -
Jeremy Feffer,
IR Contact Officer -
Faisal Sukhtian,
Independent Director -
Kurt Hilzinger,
Independent Director -
Yezan Haddadin,
Independent Director -
Andong Huang,
Director -
Julian Gangolli,
Director -
Gerd Auffarth,
Director -
Jeff Evanson,
Chief Commercial Officer -
Terry Dagnon,
Chief Operating Officer -
Alicia Tozier,
Sr. VP, Marketing & Market Access -
Joel Prieve,
Sr. VP of Commercial Operations -
Elizabeth A. Yamashita,
Advisor -
Dr. Balu N. Balasubramanian,
Advisor -
Rick Gregory,
Director of Marketing & Communications -
C Russell Iii Trenary,
CEO AND PRESIDENT -
Pte Ltd.Pillai Arun Kumar S...,
-
Ghiath M.Gms Ventures & Inv...,
-
Joe Thomas,
Director -
Pte Ltd. Bio Lexis,
10% owner -
Faisal Ghiath Gms Ventures ...,
-
Arun Kumar Pillai,
Director -
Ventures Llc Syntone,
-
Julia A Haller,